Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Devgen and Syngenta Enter Insect Control Research Partnership

Published: Monday, October 22, 2012
Last Updated: Monday, October 22, 2012
Bookmark and Share
License to access novel insect control technology.

Devgen and Syngenta have announced a six-year global license and research agreement. The partnership will enable Syngenta to add RNA interference (RNAi) technology to its crop protection pipeline.

As of April 2013, the two companies will jointly develop new biological insect control solutions based on RNAi technology.

Under the agreement, Syngenta will develop and commercialize sprayable RNAi-based crop protection products originating from Devgen.

Devgen will bolster its research activities through funding and royalties from Syngenta, consisting of an upfront technology access payment of EUR 22m and EUR 4.8m per year to fund research over the course of the agreement.

Devgen is eligible to receive royalties from Syngenta on sales of developed products.

“We are pleased to enter this research partnership with Devgen given their leading position in RNAi research and proven expertise in RNAi-based insect control,” said Sandro Aruffo, Global Head of Research and Development at Syngenta.

Aruffo continued, “This novel technology further expands our growing range of biological insect control solutions.”

“We are pleased to have Syngenta, a leading crop protection and seed company, as partner in the RNAi field. This relationship will enable Devgen to further and fully exploit the potential of this exciting technology for spray applications.” says Thierry Bogaert, CEO of Devgen.

RNAi is a naturally occurring process in all organisms, whereby an organism shuts down specific genes in its cells based on their sequence identity to a short double stranded RNA (dsRNA) molecule.

When an RNAi spray directed to a target insect pest is applied to a crop, insects that feed on the crop ingest the sprayed dsRNA.

The naturally occurring RNAi mechanism in the target insects then shuts down the insect gene that corresponds to the dsRNA. This results in effective control with no harm to beneficial insects.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Symmetry is Key to Collagen
Researchers describe how symmetry may be the key to growing collagen fibres outside the body.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!